HC Wainwright upgraded shares of Bradmer Pharmaceuticals (TSE:GLX – Free Report) to a strong-buy rating in a research report sent to investors on Thursday, Zacks.com reports.
Bradmer Pharmaceuticals Stock Performance
Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The company reported C($0.55) earnings per share for the quarter.
Further Reading
- Five stocks we like better than Bradmer Pharmaceuticals
- How to Use the MarketBeat Excel Dividend Calculator
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- What is a Low P/E Ratio and What Does it Tell Investors?
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- Using the MarketBeat Dividend Tax Calculator
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
